Open access · CC-BY
via OpenAlex
From mesenchymal roots to pluripotent reprogramming: exosomal crossroads in regenerative medicine
Movva Harsha Vardhan, Priyanka Srivastava
SLAS TECHNOLOGY · 2026
Stem-cell exhaustion
Altered intercellular communication
Stem-cell therapy
Partial reprogramming (OSK)
Human
Review
Abstract
Despite growing interest in exosome-based regenerative therapies, conventional mesenchymal stem cell (MSC) and somatic cell derived exosomes face persistent translational barriers, including donor heterogeneity, ethical constraints, limited scalability, and batch-to-batch variability. It remains unclear how far induced pluripotent stem cell (iPSC) derived exosomes can address these limitations, and how their advantages and remaining translational barriers compare with those of established MSC exosome platforms. This review synthesizes current evidence on the biology, therapeutic applications, and bioengineering of exosomes across cellular sources, with a focus on critically comparing MSC- and iPSC-derived exosomes rather than cataloguing individual sources in isolation. iPSC-derived exosomes are, on the evidence reviewed here, the more promising long-term platform; their unlimited, genetically homogeneous, and engineerable source material addresses the donor heterogeneity, ethical, and scalability limits that constrain MSC exosomes at their root, rather than merely working around them. This advantage remains largely theoretical in practice, however, since iPSC exosome production, GMP manufacturing, and clinical validation currently lag behind the more established MSC exosome pipeline. Closing that gap, rather than the underlying biological case for iPSCs, is therefore the critical bottleneck this review identifies. The first registered human trials of iPSC derived exosomes have now appeared, in stable vitiligo, atopic dermatitis, and Moyamoya disease, but these small, early phase, and dermatology or topical delivery led, underscoring that closing translational gaps, GMP compliant and AI assisted manufacturing, standardized potency and safety assays, exosome specific rather than cell inherited genomic risk assessment, and clearr regulatory pathways will determine whether either platform, or a combination of both, moves from this narrow clinical foothold to routine use.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.slast.2026.100474
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Vardhan, M.H., & Srivastava, P. (2026). From mesenchymal roots to pluripotent reprogramming: exosomal crossroads in regenerative medicine. <em>SLAS TECHNOLOGY</em>. https://doi.org/10.1016/j.slast.2026.100474
Vancouver
Vardhan MH, Srivastava P. From mesenchymal roots to pluripotent reprogramming: exosomal crossroads in regenerative medicine. SLAS TECHNOLOGY. 2026. doi:10.1016/j.slast.2026.100474.
BibTeX
@article{movva2026Fromme,
title = {From mesenchymal roots to pluripotent reprogramming: exosomal crossroads in regenerative medicine},
author = {Movva Harsha Vardhan and Priyanka Srivastava},
journal = {SLAS TECHNOLOGY},
year = {2026},
doi = {10.1016/j.slast.2026.100474},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Aging 2026
Open access · CC-BY
Therapeutic potential of stem cell-derived extracellular vesicles in aging and regeneration
Respirology 2013
Open access · OA
Mesenchymal stem cells and the lung
Journal of orthopaedic surgery and research 2026
Citation only
Progress in research on the association between mesenchymal stem cell senescence and knee osteoarthritis.
Biomedicines 2021
Open access · CC-BY
Exosomes and Micro-RNAs in Aging Process
BMC Musculoskeletal Disorders 2016
Open access · CC-BY
Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy – a review
Cell Biochemistry and Function 2020
Citation only